© The Author(s), 2018. Objective: To describe a case of severe hypertriglyceridemia in a patient receiving teriflunomide. Methods: This is a case study. Results: Our patient developed severe hypertriglyceridemia (>5000 mg/dL) while on teriflunomide. The drug was withdrawn. Resolution began over 3 weeks later. Conclusion: We describe the first probable case of teriflunomide-associated severe hypertriglyceridemia in a patient with multiple sclerosis, an adverse event previously associated with leflunomide in patients with rheumatologic diseases. Clinicians should be aware of this rare but potentially dangerous adverse event.
|Journal||Multiple Sclerosis Journal|
|Publication status||Published - 1 Sept 2018|
- multiple sclerosis